NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.68
-0.04 (-2.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.72
Open1.72
Bid1.68 x 42300
Ask1.69 x 4000
Day's Range1.68 - 1.74
52 Week Range0.90 - 2.75
Volume2,953,765
Avg. Volume7,178,512
Market Cap641.214M
Beta2.99
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.93
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Free Technical Insights on OPKO Health and Three Other Biotech Stocks

    Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...

  • 3 Top Stocks Under $5
    Motley Fool9 days ago

    3 Top Stocks Under $5

    These low-priced stocks could generate huge returns. But there are huge risks, too.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of NVAX earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 Novavax Inc Earnings Call

  • Investopedia15 days ago

    Top 3 Healthcare Penny Stocks for 2018

    The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.

  • Associated Press16 days ago

    Novavax: 1Q Earnings Snapshot

    On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 14 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswire17 days ago

    Novavax Reports First Quarter 2018 Financial Results

    GAITHERSBURG, Md., May 09, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2018. First Quarter and Subsequent Achievements: ...

  • GlobeNewswire17 days ago

    Novavax Reports First Quarter 2018 Financial Results

    GAITHERSBURG, Md., May 09, 2018-- Novavax, Inc., today announced its financial results for the first quarter ended March 31, 2018.. First Quarter and Subsequent Achievements:. In May 2018, Novavax reached ...

  • GlobeNewswire19 days ago

    Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine

    Novavax, Inc. (NVAX) today announced it has reached a significant milestone in the Prepare(TM) Phase 3 clinical trial of its respiratory syncytial virus F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization. Prepare is a global, pivotal Phase 3 clinical trial of the RSV F Vaccine, in healthy, third trimester pregnant women, which initiated in December 2015. "Reaching this enrollment target for the Prepare trial is a significant milestone in the advancement of our RSV F Vaccine franchise," said Stanley C. Erck, President and CEO of Novavax, Inc. "RSV remains an urgent global unmet medical need due to the mortality and morbidity associated with RSV disease in infants and the absence of a vaccine to prevent such disease.

  • GlobeNewswire19 days ago

    Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine

    Novavax, Inc. (NVAX) today announced it has reached a significant milestone in the Prepare™ Phase 3 clinical trial of its respiratory syncytial virus F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization. Prepare is a global, pivotal Phase 3 clinical trial of the RSV F Vaccine, in healthy, third trimester pregnant women, which initiated in December 2015. “Reaching this enrollment target for the Prepare trial is a significant milestone in the advancement of our RSV F Vaccine franchise,” said Stanley C. Erck, President and CEO of Novavax, Inc. “RSV remains an urgent global unmet medical need due to the mortality and morbidity associated with RSV disease in infants and the absence of a vaccine to prevent such disease.

  • Will Novavax Inc’s (NASDAQ:NVAX) Earnings Grow In The Years Ahead?
    Simply Wall St.20 days ago

    Will Novavax Inc’s (NASDAQ:NVAX) Earnings Grow In The Years Ahead?

    Novavax Inc’s (NASDAQ:NVAX) released its most recent earnings update in December 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investors TodayRead More...

  • GlobeNewswire23 days ago

    Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018

    GAITHERSBURG, Md., May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial ...

  • GlobeNewswire24 days ago

    Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018

    GAITHERSBURG, Md., May 02, 2018-- Novavax, Inc. today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, ...

  • 3 Stocks That Could Put Amazon's Returns to Shame
    Motley Fool26 days ago

    3 Stocks That Could Put Amazon's Returns to Shame

    Investors looking for the next Amazon should consider an e-commerce facilitator, a vaccine developer, and a supplier of autonomous car parts.

  • Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
    Zackslast month

    Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

    Is Novavax, Inc. (NVAX) Outperforming Other Medical Stocks This Year?

  • Don't Get Greedy With Novavax, Inc. Stock
    Motley Foollast month

    Don't Get Greedy With Novavax, Inc. Stock

    Novavax's abysmal track record should be a huge red flag for potential shareholders.

  • 3 Biotech Stocks That Will Thrive Amid Market Instability
    InvestorPlacelast month

    3 Biotech Stocks That Will Thrive Amid Market Instability

    The U.S. stock market is facing a severe volatility since the last couple of months despite a strong start this year. This downside can mainly be attributable to a potentially damaging trade war between the world’s two largest economies, United States and China, since this February.Source: Shutterstock

  • Buy Novavax After Its Latest Pullback?
    Motley Foollast month

    Buy Novavax After Its Latest Pullback?

    Novavax has a couple of promising experimental vaccines. But could even more dilution be around the corner?

  • GlobeNewswirelast month

    Novavax Announces Closing of Public Offering

    GAITHERSBURG, Md., April 16, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced ...

  • GlobeNewswirelast month

    Novavax Announces Closing of Public Offering

    GAITHERSBURG, Md., April 16, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced the closing of the underwritten ...

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Novavax and Pfizer

    NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on ...

  • Here's Why Novavax, Inc. Is Sinking
    Motley Foollast month

    Here's Why Novavax, Inc. Is Sinking

    Shares plunged after the clinical-stage vaccine maker gave details on the pricing of its recently announced common stock offering.

  • MarketWatchlast month

    Novavax's stock plunges on heavy volume after public offering prices at deep discount

    Shares of Novavax Inc. tumbled 16% in active premarket trade Thursday, after the biotechnology company said its relatively large public offering of stock priced at a deep discount. Volume topped 8.5 million ...

  • GlobeNewswirelast month

    Novavax Prices Public Offering of Common Stock

    GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced ...

  • GlobeNewswirelast month

    Novavax Prices Public Offering of Common Stock

    GAITHERSBURG, Md., April 11, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it has priced an underwritten ...

  • Novavax announces plans for public offering
    American City Business Journalslast month

    Novavax announces plans for public offering

    Details of the offering — including how many shares the company would sell, at what price, and when — are still being hammered out.